GlassScriptPhysician profile
Uno O Barcelli
NPI 1932130721
$11,733.07
in general payments reported to CMS, 2019-2025
30 companies · $3,086 in 2025
The $3,086 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $250 · 2021: $1,213 · 2022: $1,831 · 2023: $2,073 · 2024: $2,611 · 2025: $3,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,545 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,545.13 |
| Education | $224.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,572.43 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,342.64 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $1,315.86 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $980.82 | 2020-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $850.06 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $637.53 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $582.79 | 2022-2025 | Thiola |
| Opko Pharmaceuticals, LLC | $571.32 | 2019-2024 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $536.58 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $499.32 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $440.69 | 2019-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.60 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $291.75 | 2022-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $269.28 | 2021-2025 | Shingrix, Benlysta |
| Vifor Pharma, INC. | $268.31 | 2019-2024 | Veltassa, Korsuva |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $256.87 | 2021-2025 | Auryxia, Vafseo |
| Ani Pharmaceuticals, INC. | $181.56 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $179.67 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $127.76 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $114.80 | 2020-2023 | Injectafer |
| Baxter Healthcare | $96.41 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $78.50 | 2019-2025 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $72.68 | 2023-2024 | Edarbi, Edarbyclor |
| Arbor Pharmaceuticals, INC. | $28.48 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $25.86 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.48 | 2022 | |
| Scpharmaceuticals INC. | $22.53 | 2025 | |
| Shield Therapeutics INC | $19.10 | 2025 | |
| Amicus Therapeutics, INC. | $14.81 | 2022 | |
| Mallinckrodt Enterprises LLC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uno Barcelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.